Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flecainide: a new antiarrhythmic agent.

J C Somberg, D Tepper

    American Heart Journal
    |October 1, 1986
    PubMed
    Summary
    This summary is machine-generated.

    Physicians should assess premature ventricular contractions (PVCs) and myocardial vulnerability for sudden death risk. Flecainide acetate effectively reduces PVCs and prevents ventricular tachycardia induction, offering a potential treatment for both triggers and substrate.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A challenge to America.

    American journal of therapeutics·2001
    Same author

    A new therapeutic millennium [correction of millenium].

    American journal of therapeutics·2001
    Same author

    Stem-cell research.

    American journal of therapeutics·2001
    Same author

    Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans.

    American journal of therapeutics·2001
    Same author

    Adverse drug reaction reporting.

    American journal of therapeutics·2001
    Same author

    Class effects of pharmaceuticals and therapeutic interchangeability.

    American journal of therapeutics·2001
    Same journal

    Stratified Medicine with Eplerenone for Myocardial Infarction or Injury and No obstructive Coronary Arteries: A Registry-Based Basket Trial.

    American heart journal·2026
    Same journal

    Revised Lipid-Lowering Therapy Guidelines in a Nationally Representative Sample.

    American heart journal·2026
    Same journal

    Cardiometabolic Health of Low- and Higher-Income Adults in the United States, 2009-2023.

    American heart journal·2026
    Same journal

    Moving Beyond Technical Capability to Regulatory Integration for Digital Health Technology Devices-Brief Communication from the Cardiovascular Sciences Research Consortium.

    American heart journal·2026
    Same journal

    THE SOCIETY OF CRITICAL CARE CARDIOLOGY - RATIONALE, BLUEPRINT, AND LESSONS LEARNED IN THE CREATION OF A NEW MULTIDISCIPLINARY PROFESSIONAL ORGANIZATION.

    American heart journal·2026
    Same journal

    DOAC Score Among Patients Receiving Vitamin K Antagonists.

    American heart journal·2026
    See all related articles

    Area of Science:

    • Cardiology
    • Electrophysiology
    • Pharmacology

    Background:

    • Sudden cardiac death is linked to premature ventricular contractions (PVCs) acting as triggers and myocardial vulnerability as the substrate.
    • Assessing both PVC frequency and myocardial vulnerability is crucial for accurate risk stratification in patients at risk for sudden death.

    Purpose of the Study:

    • To evaluate the efficacy of flecainide acetate in managing PVCs and preventing ventricular tachycardia (VT) induction.
    • To determine if flecainide acetate can address both the trigger (PVCs) and substrate (myocardial vulnerability) components of sudden cardiac death.

    Main Methods:

    • Utilized Holter monitoring to assess PVC frequency.
    • Employed programmed electrical stimulation (PES) to evaluate myocardial vulnerability and VT induction.

    Related Experiment Videos

  • Administered flecainide acetate at a reduced dosage (100 mg twice daily).

    • Main Results:

    • Flecainide acetate significantly reduced PVC frequency.
    • The drug effectively prevented VT induction during PES testing.
    • Flecainide acetate demonstrated efficacy in addressing both trigger mechanisms and myocardial vulnerability.

    Conclusions:

    • Flecainide acetate, at a reduced dosage, is effective in decreasing PVC frequency and preventing VT induction, addressing key factors in sudden death.
    • This antiarrhythmic agent offers a potential therapeutic option for managing both PVC triggers and the arrhythmogenic substrate.
    • Caution is advised regarding flecainide's potential to exacerbate arrhythmias in some patients due to its effects on depolarization and refractoriness.